Home
overview

Oligonucleotide therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules. They bring about the ability to affect targets that have been considered “non-draggable”. Heavy investments in oligonucleotide therapeutic discovery have created an emerging market need for drug delivery technologies.
 

Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.
 

Drug discovery is an exceptionally complex undertaking. The questions to ask and hurdles to overcome are many. What is of paramount importance is that the initial steps in the process are made as qualified as possible, and unfortunately, costly examples of the opposite are not uncommon in the industry. To establish a strong and competitive program, contribution from many disciplines is needed. This workshop will focus on the initial parameters for drug discovery and try to define how a “good” program may look like. It is intended that the workshop is interactive so detailed discussions between the presenters and the audience is enticed.

• Gain insight into the complex drug discovery process of oligonucleotide-based therapeutics from project start to finish
• Listen to case studies revealing crucial aspects of delivery and how to tackle delivery related challenges
• Deep dive into in silico structure-based molecular modeling of oligonucleotides
• Develop the right controls for in vivo and in vitro assays for securing high translation rates
 

  • RNA Biology/Discovery
  • Novel Therapeutic Modalities
  • Innovation Technologies
  • C-level Scientific Executives
  • Formulation and Drug Delivery
  • Clinical Research and Development
  • Cell Biology

Accanis Therapeutics; Advanced Cell Diagnostics – A Bio-Techne Brand; Aescap 2.0; Alnylam Pharmaceuticals UK & Ireland; AmpTec GmbH; Aseptic Technologies SA; AstraZeneca; Bachem AG; BianoGMP; BioNTech IMFS GmbH; BioNTech RNA Pharmaceuticals; Boehringer Ingelheim Pharma GmbH & Co. KG; Calithera Biosciences; CEPI - Coalition for Epimemic Prepardness Innovation; Chemgenes Corporation; Curevac Ag; Dicerna Therapeutics.; Duke University School of Medicine; Ethris GmbH; Exicure Inc.; F.Hoffmann-La Roche AG; GSK; Horizon Discovery; InteRNA Technologies BV; Intertek; Lipocalyx; MedImmune; MHRA; MiNA Therapeutics; N4 Pharma UK Limited; New England Biolabs; NHS Blood and Transplant Authority; Nitto Avecia; NOF Europe GmbH; Nouscom SRL; ProQR Therapeutics; RCSI; RCSI Royal College of Surgeons in Ireland,; RNA Medco; ROCHE; Roche Diagnostics Deutschland GmbH; Roche Innovation Center; Russell Publishing Ltd; Sanofi; Sanofi-Aventis Deutschland GmbH; Takeda Development Centre Europe Ltd.; TCR Solutions; The Italian Institute of Technology; The RNA Medicines Company; Thermo Fisher Scientific; University Medicine Mainz Hospital; University Of Portsmouth; University Of Surrey; Yuria Pharma;

Workshop programme

13:00 Registration & Coffee

13:30 Opening Remarks From Workshop Leaders

Troels Koch

Troels Koch, Independent Consultant , Roche A/S
View Bio

Maj  Hedtjärn

Maj Hedtjärn, Head of Drug Discovery, RNA Therapeutics Research, Roche A / S
View Bio

13:40 Target and indication

  • How to make the best selection of target and indication to favor oligonucleotide therapeutics in relation to competing modalities?
  • Disease - target - modality triangulation: Where to begin, any preference?
  • Troels Koch

    Troels Koch, Independent Consultant , Roche A/S
    View Bio

    Maj  Hedtjärn

    Maj Hedtjärn, Head of Drug Discovery, RNA Therapeutics Research, Roche A / S
    View Bio

    14:20 Delivery

  • Case stories and latest status - encapsulation or conjugation
  • To what extent is delivery the driver for program identification?
  • Troels Koch

    Troels Koch, Independent Consultant , Roche A/S
    View Bio

    Maj  Hedtjärn

    Maj Hedtjärn, Head of Drug Discovery, RNA Therapeutics Research, Roche A / S
    View Bio

    15:00 Afternoon Tea

    15:30 Advancing in silico discovery

  • Going beyond sequence-based bioinformatics 
  • Structure based molecular and/or quantum mechanical modelling?
     
  • Troels Koch

    Troels Koch, Independent Consultant , Roche A/S
    View Bio

    Maj  Hedtjärn

    Maj Hedtjärn, Head of Drug Discovery, RNA Therapeutics Research, Roche A / S
    View Bio

    16:10 In vitro and in vivo assays

  • Toxicity and potency validation 
  • How to establish the right controls and secure high degree of translation?
  • Troels Koch

    Troels Koch, Independent Consultant , Roche A/S
    View Bio

    Maj  Hedtjärn

    Maj Hedtjärn, Head of Drug Discovery, RNA Therapeutics Research, Roche A / S
    View Bio

    16:50 Closing Remarks from workshop leaders

    Troels Koch

    Troels Koch, Independent Consultant , Roche A/S
    View Bio

    Maj  Hedtjärn

    Maj Hedtjärn, Head of Drug Discovery, RNA Therapeutics Research, Roche A / S
    View Bio

    17:00 End of Workshop

    +

    FEATURED SPEAKERS

    Maj  Hedtjärn

    Maj Hedtjärn

    Head of Drug Discovery, RNA Therapeutics Research, Roche A / S
    Troels Koch

    Troels Koch

    Independent Consultant , Roche A/S

    Maj Hedtjärn

    Head of Drug Discovery, RNA Therapeutics Research, Roche A / S
    Maj  Hedtjärn

    Maj Hedtjärn is an experienced leader in the field of RNA Therapeutics Drug Discovery, Research and Innovation with more than 14 years of R&D experience from biotech and big pharma and more than 10 years of leadership experience.
    At Santaris Pharma A/S (2006 - 2014), Maj was part of building a strong and diverse pipeline in Oncology, Infectious and Metabolic diseases. She was further leading the LNA Drug Discovery programs with all Santaris´ pharma partners (Enzon Pharmaceuticals, GSK, Shire, Wyeth, Pfizer, BMS and Roche) and played an important role also in the Alliance management.
    At Roche (2014 - 2019) she took up the position as VP & Head of Drug Discovery, RNA Therapeutics Research, where she was responsible for building and advancing a strong and competitive pipeline of RNA Therapeutics Drugs across several disease areas. She was making strategic project and portfolio decisions, taking part in target selection and prioritization activities and ensuring rapid progress of the entire portfolio. She was further responsible for the biological characterization of drug candidates in vitro and in vivo, for refinement of the Drug Discovery process and for improvement of the LNA platform. As part of the leadership team at Roche Innovation Center Copenhagen, Maj took part in all aspects of executive decision making, company strategy, IP strategy and prosecution, people management and building an agile and innovative company culture.
     

    Troels Koch

    Independent Consultant , Roche A/S
    Troels Koch

    Troels Koch (TK) has 20 years’ experience in the international life science and biopharmaceutical industry. Founder of several biotech companies of which Exiqon A/S and Santaris Pharma A/S are the most commonly known. Santaris Pharma A/S was successfully exited in August 2014 – acquired by Roche, and Exiqon A/S was acquired in 2016 by Qiagen. TK has been positioned in company management teams and taken part in all aspects of executive decision making: Company strategy, VC fundraising, deal makings, partnering, IP strategy & prosecution, drug discovery and R&D. TK pioneered LNA therapeutics and has been responsible for keeping LNA antisense science and technology at an international lead position. He has worked with RNA therapeutics for 20 years and taken an active role in all steps of oligonucleotide drug discovery and development. TK has built R&D organizations up to 75 co-workers, held 100+ invited presentations at international conferences and is author of 80+ peer reviewed publications.

    VENUE

    Holiday Inn Kensington Forum

    97 Cromwell Road , London, United Kingdom

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out